Materials of Construction Based on Recovery Data for Cleaning Validation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Materials of Construction Based on Recovery Data for Cleaning Validation
The material of construction is a factor in the recovery of residue in cleaning validation. An analysis of existing recovery data showed that recovery factors for drug products on various materials of construction may be categorized into several groupings.


Pharmaceutical Technology



Table III: Second highest group mean recovery factor (RF).
Representative material from each group. This result implies that RF for any new product can be estimated from a material within this group with a standard deviation of 13 units. The mean RF for each material in the group is shown in Table III. The most conservative choice for a representative material is the lowest mean recovery, which is nylon. The mean or median recovery of the materials in the group is either brass or Nylaclast Oilon. These three materials, however, represent a very small percentage of the actual equipment. The most logical and practical representative material for recovery studies is stainless steel. Stainless steel is included in the group, is not on the extreme high end, and is the major component of manufacturing equipment. The RF from other material groups can be determined as exceptions to this group.


Table IV: Average recovery data.
Test case. As a test of the data analysis, a recent study measured the percent recovery of a development compound, MK-0524, and niacin. The study included five materials of construction from the largest group of recovery materials (see Tables II and III), including stainless steel. The study results, shown in Table IV and Figure 2, confirm the overall study conclusions. The average recoveries on the materials of construction were well within the expected Table III value 15% range.


Figure 2: Recovery variability. (FIGURE 2: MERCK & CO. INC.)
The repeatability for these results was better than typical. The standard deviation estimate of 4.3 for repeated tests across different materials compared favorably to the data in the large data set, where standard deviations were typically 13 to 14 units. The tighter data set was most likely the result of study parameters. The study included a single site and relatively large number of recoveries for each compound, conducted in the same time frame following the same procedure.

The standard deviation was tighter for this data set, so it was possible to detect statistically significant differences among some materials for MK-0524; however, the confidence intervals for recovery estimated on the five different materials were all well within the 15% expected range. The confidence intervals for niacin tested on five different materials were all overlapping.

Conclusion


Statistical approach for the recovery analysis.
The analysis showed that a recovery study conducted at one manufacturing site using stainless steel could serve as a representative material of construction for most materials used in drug-product manufacturing applicable across multiple sites.

Acknowledgment

The authors acknowledge the contributions of the 16 site representatives, without whom, this study would not have been possible.

Richard J. Forsyth* is an associate director of worldwide GMP quality with Merck & Co., Inc., WP53C-307, West Point, PA 19486, tel. 215.652.7462, fax 215.652.7106,
Julia C. O'Neill is a senior scientific fellow of regulatory and analytical sciences, and Jeffrey L. Hartman is a validation manager of regulatory and analytical sciences at Merck & Co., Inc.

* To whom correspondence should be addressed.

Submitted: Mar. 26, 2007. Accepted June 4, 2007.

References

1. FDA, Guide to Inspection of Validation of Cleaning Processes (FDA, Rockville, MD) , July 1993).

2. R.J. Forsyth and D. Haynes, "Cleaning Validation in a Pharmaceutical Research Facility," Pharm. Technol. 22 (9), 104–112 (1998).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here